TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety Evaluation of Clopidogrel Sulfate in Patients With Peripheral Arterial Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Documented symptomatic peripheral arterial disease (one or both of the following two primary criteria must be satisfied):~* Current intermittent claudication with Ankle Brachial Index (ABI) \< 0.90~* A history of intermittent claudication together with previous related intervention in a leg~Exclusion Criteria:~* Patients who had acute atherothrombotic events or any invasive therapies within 30 days before the randomization, or patients who planned any invasive therapies within 12 weeks after the randomization~* Bleeding diathesis, coagulopathy and present bleeding disease~* Previous intracranial bleeding or hemorrhagic stroke~* Uncontrolled hypertension~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clopidogrel (Type: EXPERIMENTAL): 75 mg clopidogrel once daily from Day 1 to Week 12
- Ticlopidine (Type: ACTIVE_COMPARATOR): 200 mg ticlopidine once daily from Day 1 to Week 12

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety of Lumiracoxib in Patients With Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>=50 years old~* Primary osteoarthritis in hip, hand, knee or spine for at least 3 month~* Pain in the target joint of moderate intensity~* Written informed consent~Exclusion Criteria:~* Secondary osteoarthritis~* Active upper gastro intestinal tract ulceration~* Inflammatory joint disease~* Gout~* Clinically significant hepatic or renal disease~Other in and exclusion criteria may apply

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
For additional information, please contact the BMS oncology clinical trial information service at 855-216-0126 or email MyCancerStudyConnect@emergingmed.com. Please visit www.BMSStudyConnect.com for more information on clinical trial participation.~Inclusion Criteria:~* Documented progression from most recent line of therapy~* Measurable disease~* 1 to 3 prior lines of therapy~  * Subjects may be proteasome inhibitor naive or have received prior proteasome inhibitor therapy provided all the following criteria are met:~    1. The subject did not discontinue any proteasome inhibitor due to intolerance or grade ≥ 3 toxicity~   2. The subject is not refractory to any proteasome inhibitor, defined as progression during treatment or within 60 days after the last dose~   3. The subject previously achieved a partial response (PR) or better to previous proteasome inhibitor (PI)~Exclusion Criteria:~* Monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma, or Waldenstrom's macroglobulinemia~* Active plasma cell leukemia~* Known Human immunodeficiency virus (HIV) infection or active hepatitis A, B, or C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: Elotuzumab + Bortezomib + Dexamethasone (Type: EXPERIMENTAL): On days of Elotuzumab infusion: Dexamethasone (8mg IV + 8mg Oral) will be administered other days Dexamethasone 20 mg Oral will be administered
- Arm B: Bortezomib + Dexamethasone (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Modulating Brain Activity to Improve Goal-directed Physical Activity in Older Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must live within subsidized housing in the Boston area~* Self-report of exercising, on average, less than 150 minutes of at least moderate-intensity exercise per week, as determined by phone-screen completion of the International Physical Activity Questionnaire-Short Form (IPAQ short)~Exclusion Criteria:~* An inability to ambulate without the assistance of another person (canes or walkers allowed)~* Self-report of physician-diagnosed dementia, more than moderate cognitive impairment defined as a Montreal Cognitive Assessment (MoCA) score \<21, or an inability to understand the study protocol as determined by study staff~* A clinical history of stroke, Parkinson's disease or parkinsonian syndromes, multiple sclerosis, normal pressure hydrocephalus or other movement disorder affecting gait~* Any report of severe lower-extremity arthritis or physician-diagnosis of peripheral neuropathy~* Use of antipsychotics, anti-seizure, benzodiazepines, or other neuroactive medications~* Severe depression defined by a Geriatric Depression Scale score greater than 11~* Any report or physician-diagnosis of schizophrenia, bipolar disorder or other psychiatric illness~* Any unstable medical condition~* Resting systolic blood pressure is higher than 180 mmHg~* Contraindications tor tDCS, including reported seizure within the past two years, use of neuro-active drugs, self-reported presence of specific implanted medical devices (e.g., deep brain stimulator, medication infusion pump, cochlear implant, pacemaker, etc.), or the presence of any active dermatological condition, such as eczema, on the scalp

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Behavioral intervention plus tDCS (Type: EXPERIMENTAL): This intervention will consist of a two-month, personalized, goal-based counseling approach to promote physical activity. Over the first two weeks of the behavioral intervention, participants will also received 10, once-daily, 20-minute sessions of transcranial direct current stimulation (tDCS) designed to increase the excitability of the left dorsolateral prefrontal cortex.
- Behavioral intervention plus sham stimulation (Type: ACTIVE_COMPARATOR): This intervention will consist of a two-month, personalized, goal-based counseling approach to promote physical activity. Over the first two weeks of the behavioral intervention, participants will also received 10, once-daily, 20-minute sessions of sham stimulation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Barbershop Talk: HIV Prevention for African American Heterosexual Men

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Unprotected sex in the past three months~* Identify as Black or African American~Exclusion Criteria:~* Having been in an HIV prevention research study in the last six months~* Reporting a history in the past five years of injection drug use~* Reporting a history in the past five years of having sex with other men~* Reporting an HIV-positive serostatus~* Inability to understand spoken English.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- BTWB intervention (Type: EXPERIMENTAL): Barbershops are assigned to either experimental or active control condition. Men recruited from experimental barbershops receive a single-session group intervention focused on HIV prevention.
- Cancer prevention and screening (Type: ACTIVE_COMPARATOR): Barbershops are assigned to either experimental or control condition. Men recruited from control barbershops receive information on cancer prevention and control.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Puerarin Injection on Carotid Intima-Media Thickness in Patients With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients with a definite diagnose of rheumatoid arthritis(RA) were included if they met the classification criteria for RA established by the American Rheumatism Association (ACR) and European League Against Rheumatism (EULAR) in 2010~* aged from 18 to 75 years~* without conflict to the written, informed consent signed prior to the enrollment~* no severe hepatic or renal disorders~* no known carotid artery stenosis~* no coagulation disorders~* no hypertension~Exclusion Criteria:~* being in pregnancy, lactation period or under a pregnancy plan~* being allergic to the test drug~* not compatible for the trial medication~* without full legal capacity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Puerarin injection 400 mg (Type: EXPERIMENTAL): Patients were administrated with 400 mg intravenously infused puerarin injection once a day. Puerarin injection was prepared in 250 mL 0.9% sodium chloride injection before the use. The treatment course consisted of 2 weeks followed by a 15-day interval for 24 weeks. Furthermore, patients receive stable treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, statins, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.
- Control (Type: SHAM_COMPARATOR): Patients receive routine anti-rheumatic care only. Patients receive stable treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, statins, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Alphagan on Retinal Blood Flow Autoregulation and Motion Detection in Patients With Normal Pressure Glaucoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Eligible subjects will have no history of IOP \> 24 mm Hg in either eye.~* All subjects will have open angles on gonioscopy with the filtering portion of the trabecular meshwork visible for 360° in both eyes.~* Previously or newly diagnosed patient are required to have HVFs that are reliable and show loss consistent with nerve fiber layer atrophy.~* Patients with glaucoma-like discs (CDR\>0.7 in either eye) and normal/reliable visual fields who the PI has opted to observe without treatment will enter the study if they meet the other study criteria.~* In order to facilitate the retinal blood flow measurements, only subjects with refractive error within the range -10 to +10 diopters, no lens opacities greater than 1+ cortical spokes or 2+ nuclear sclerosis, and pupillary dilation of at least 6 mm following mydriasis will be included.~Exclusion Criteria:~* Patients with evidence of exfoliation or pigment dispersion syndrome in either eye.~* Patients with a cup/disc ratio \> 0.8.~* Known history of allergy to brimonidine.~* Patients already on treatment with brimonidine will be excluded from the study.~* Diabetic retinopathy.~* History of ocular laser or incisional surgery in either eye.~* Use of systemic alpha-2 blockers.~* Pregnant or planning to become pregnant.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Patients with RVD (Type: EXPERIMENTAL): Patients who exhibited retinal vascular dysregulation at the initial visit. Intervention: brimonidine 0.15% three times per day for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Maintenance of Effect of Duloxetine in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have pain due to bilateral peripheral neuropathy caused by Type I or Type II diabetes with the pain beginning in the feet and present for at least 6 months.~* May not be pregnant and agree to utilize medically acceptable and reliable means of birth control during participation in the study.~* Score of 4 or greater on the Brief Pain Inventory on the 24-hour average pain item.~Exclusion Criteria:~* History of substance abuse or dependence within the past year, excluding nicotine and caffeine.~* Serious or unstable cardiovascular, hepatic (acute liver injury such as hepatitis or severe cirrhosis),kidney, respiratory, or blood disorder, seizure disorder, problems with peripheral vascular disease, or other medical conditions or psychiatric conditions that would hinder your participation or be likely to lead to hospitalization during the course of the study.~* Taking monoamine oxidase inhibitor (MAOI) within 14 days of starting the study or the potential need to take during or within 5 days after discontinuation from the study.~* Treatment with fluoxetine within 30 days of starting the study.~* Unstable blood sugar control and uncontrolled or poorly controlled hypertension.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Duloxetine (Type: EXPERIMENTAL): All subjects receive 30 mg once daily (QD), by mouth (per os - PO) for 1 week followed by duloxetine 60 mg QD, PO for 7 weeks, then maintenance at 60 mg QD, PO for responders to 6 months and rescue at 120 mg QD, PO for non-responders to 6 months. Patients beginning maintenance at the 60 mg QD dose could be increased to the 120 mg QD level if they did not maintain appropriate level of response throughout the maintenance period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the ClariFix™ Cryotherapy Device in Subjects With Chronic Rhinitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject is \>21 years of age~2. Subject has moderate to severe symptoms of rhinorrhea (individual symptom rating of 2 or 3), mild to severe symptoms of congestion (individual symptom rating of 1, 2 or 3) and a minimum TNSS score of 4 (out of 12) at the time of the treatment visit, which have been present for \> 6 months.~3. Subject has had documented allergy test within the last 10 years that defines whether or not subject has allergies to perennial and seasonal allergens or is willing to have one performed prior to study exit.~4. Subject has been dissatisfied with medical management, defined as usage of intranasal steroids for a minimum of 4 weeks without adequate symptom relief by the subject's assessment.~5. Subject has signed IRB-approved informed consent form~Exclusion Criteria:~1. Subject has clinically significant anatomic obstructions that in the investigator's opinion limit access to the posterior nose, including but not limited to septal deviation or perforation, nasal polyps, sinonasal tumor.~2. Subject has had any prior sinus or nasal surgery that significantly alters the anatomy of the posterior nose.~3. Subject has active nasal or sinus infection.~4. Subject has moderate to severe ocular symptoms.~5. Subject has a history of nosebleeds in the past 3 months.~6. Subject has a history of rhinitis medicamentosa.~7. Subject has had prior head or neck irradiation~8. Subject has active coagulation disorder or is receiving anti-coagulants which cannot be safely stopped for 4 weeks (excluding aspirin).~9. Subject is pregnant.~10. Subject is participating in another clinical research study.~11. Subject has an allergy or intolerance to anesthetic agent.~12. Subject has cryoglobulinemia, paroxysmal cold hemoglobinuria, cold urticaria, Raynaud's disease, and/or, open and/or infected wounds at or near the target tissue.~13. Any physical condition that in the investigator's opinion would prevent adequate study participation or pose increased risk.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment with the ClariFix Device (Type: EXPERIMENTAL): Bilateral ablation of nasal tissue for treatment of chronic rhinitis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aliskiren for Proteinuric IgAN Despite Angiotensin Blockade

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female 18 - 70 years of age~* Histologic diagnosis of IgA nephropathy~* Proteinuria \> 1 g/day or UPC \> 1 mg/mg or 113 mg/mmol at least twice~* Receiving treatment with the maximum dose of ARB for at least 3 months~* Patients who are willing to give written, informed consent~Exclusion Criteria:~* eGFR \< 15 ml/min/1.73 sq.m~* UPC \>5000 mg/g or 570 mg/mmol, or \<500 mg/g or 57 mg/mmol~* Serum K+ \> 5.2 mmol/L~* Presence of bilateral renal artery stenosis~* Presence of diabetes mellitus~* Renal histology showing pathologies other than IgAN~* Known allergy to ARB or DRI~* Patients on ARB/ACEi combination within 12 weeks of randomization~* Concurrent treatment with corticosteroids, Nsaid, or immunosuppressant~* Patients with connective tissue disease or obstructive uropathy~* Patients with malignancy or conditions severely limiting life expectancy~* Female who are pregnant or intending to conceive~* Female of child-bearing age unwilling to practice contraception~* Patients who are unable to give informed consent~* Patients simultaneously participating in another study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Aliskiren (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Identification and Evaluation of Endogenous Markers for the Assessment of CYP3A Activity

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age: Between 20 to 50 years of age, inclusive~* Weight: Between 45 to 95 kg, within 17 - 28 of Body Mass Index~* Menstruation cycle between 21 to 35 without contraceptive~* Subject who agree contraception during the study~* Subject who are reliable and willing to make themselves available during the study period, are willing to follow the study protocol, and give their written informed consent voluntarily~Exclusion Criteria:~* History of hypersensitive reaction to medication (midazolam, ketoconazole, rifampicin)~* History of significant clinical illness needs medical caution, including cardiovascular, immunologic, hematologic, neuropsychiatric, respiratory, gastrointestinal, hepatic, or renal disease or other chronic disease history or evidence of drug abuse~* A subject whose lab test results are as follows; Liver function test (AST, ALT, GGT, ALP, LDH, Total bilirubin) \> 1.25 X upper limit of reference range~* A subject whose SBP is over 140 mmHg or below 90 mmHg and DBP is over 100 mmHg or below 50 mmHg~* Presence or history of drug abuse or positive result in urine drug screening test~* Blood donation during 2 months or apheresis during 1 month before the study~* Use any prescriptive medication, Korean traditional medication not considered acceptable by the clinical investigator during the last 14 days period before first dosing, or use any OTC medication not considered acceptable by the clinical investigator during the last 7 days period before first dosing (if used medication is considered acceptable by investigator, patients can be included)~* Use of alcohol over 21 units/weeks~* Smoker who smoke more than 10 cigarettes per day~* Participation in clinical trials of any drug within 60 days prior to the participation of the study~* Use of grapefruit juice within 1 week before first dose~* Use of caffeine drink within 3 days before first dose~* Subject pregnant or breast-feeding~* Judged to be inappropriate for the study by the investigator

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Midazolam (Type: EXPERIMENTAL): period 1: midazolam 1 mg IV single dose administration. period 2: midazolam 1 mg IV single dose after ketoconazole 400 mg oral dosing for 3 days.~period 3: midazolam 2.5 mg IV single dose after rifampicin 600 mg oral dosing for 10 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete